GC
Kintor Pharma prices IPO high to net $240m
Kintor Pharmaceutical has notched another success for the healthcare sector, raising HK$1.86bn ($240m) from its IPO after pricing the deal at the top of the marketed range.
The Mainland-based firm hit the market last week, following three other Chinese healthcare-related issuers that have listed in Hong Kong since March. The sector has been defiant through the coronavirus crisis, remaining one of the few popular sectors, running counter-cyclical to downward trending global financial markets.
Kintor Pharma kicked ...Already a subscriber? Login
